Annette S. Little

Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Annette S. Little, Kathryn Balmanno, Matthew J. Sale et al. · Science Signaling · 2011 · 204 citations

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

Victoria Chell, Kathryn Balmanno, Annette S. Little et al. · Oncogene · 2012 · 141 citations

Gatekeeper Mutation, Cell Signaling, Receptor Tyrosine Kinase +9

Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance

Carlos le Sage, Steffen Lawo, Prince Panicker et al. · Scientific Reports · 2017 · 61 citations · Full text

A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook

Annette S. Little, Kathryn Balmanno, Matthew J. Sale et al. · Science Signaling · 2011 · 44 citations

Increasing the performance of pooled CRISPR–Cas9 drop-out screening

Benedict C. S. Cross, Steffen Lawo, C Archer et al. · Scientific Reports · 2016 · 44 citations · Full text